Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

Future Oncology

Volumn 1, Issue 6, 2005, Pages 719-731

  Karp, Judith E ^a   Lancet, Jeffrey E ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

farnesylation; farnesyltransferase inhibitor; multiple myeloma; myeloid malignancies; signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; QUINOLONE DERIVATIVE; TIPIFARNIB;

BLOOD DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HEMATOLOGIC NEOPLASMS; HUMANS; QUINOLONES;

EID: 34248210118     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.719     Document Type: Article

References (72)

1. End DW: Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New Drugs 17, 241-258 (1999).
2. Rowinsky, EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17, 3631-3652 (1999).
3. Sebti SM, Der CJ: Searching for the elusive targets of farnesyltransferase inhibitors. Nature Rev. Cancer 3, 945-951 (2003).
4. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366, 643-654 (1993).
5. Lowy DR, Willumsen BM: Function and regulation of ras. Ann. Rev. Biochem. 62, 851-891 (1993).
6. Khosvari-Far R, Cox AD, Cato K, Der CJ: Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ. 3, 461-469 (1992).
7. Mackenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G: Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood 93, 2043-2056 (1999).
8. Sawyers CL, McLaughlin J, Witte ON: Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181, 307-313 (1995).
9. Kardinal C, Konkol B, Lin H et al.: Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 98, 1778-1781 (2001).
10. Lancet JE, Karp JE: Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102, 3880-3889 (2003).
11. Reuter CWM, Morgan MA, Bergmann L: Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96, 1655-1669 (2000).
12. Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y: Microarray analsyis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 4, 56 doi; 10.1186/1471-2407-4-56 (2004).
13. Burgering BM, Coffer PJ: Protein kinase B (c-AKT) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599-602 (1995).
14. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell. Biol. 10, 262-272 (1998).
15. Klippel A, Escobedo MA, Wachowicz MS et al.: Activation of phosphatidylinositol-3 kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell. Biol. 18, 5699-5711 (1998).
16. Grandage VL, Gale RE, Linch DC, Khwaja A: PI3-kinase is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-B, MAPkinase and p53 pathways. Leukemia 19, 586-594 (2005).
17. Jiang K, Coppola D, Crespo NC et al.: The phosphoinositide 3-OH/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol. 20, 139-148 (2000).
18. Bellamy WT, Richter L, Sirjani D et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97, 1427-1434 (2001).
19. Dias S, Hattori K, Zhu Z et al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521 (2000).
20. Fiedler W, Graeven U, Ergun S et al.: Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89, 1870-1875 (1997).
21. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3- kinase/Akt signaling pathway in Ha-rastransformed cells thourhg a hypoxia inducible factor-1 transcriptional element. Blood 90, 3322-3331 (1997).
22. Chin L, Tam A, Pomerantz J et al.: Essential role for oncogenic Ras in tumour maintenance. Nature 300, 368-472 (1999).
23. Rak J, Mitsuhashi Y, Bayko L et al.: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575-4580 (1995).
24. Delmas C, End D, Rochaix P, Favre G, Toulas C, Cohen-Jonathan E: The Farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin. Cancer Res. 9, 6062-6068 (2003).
25. Delmas C, Heliez C, Cohen-Jonathan E et al.: Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer 100, 43-48 (2002).
26. Ridley AJ, Hall A: The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389-399 (1992).
27. Armstrong SA, Hannah VC, Goldstein JL, Brown MS: CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl tp RhoB: J. Biol. Chem. 270, 7864-7868 (1995).
28. Adamson P, Marshall CJ, Hall A, Tilbrook PA: Post-translational modifications of p21rho proteins. J. Biol. Chem. 267, 20033-20038 (1992).
29. Prendergast CG, Khosravifar R, Solski PA et al.: Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10, 2289-2296 (1995).
30. Du W, Lebowitz PF, Prendergast CG: Cell growth inhibition by farnesyltransferasze inhibitors is mediated by a gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19, 1831-1840 (1999).
31. Lebowitz PF, Casey PJ, Prendergast CG, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB: J. Biol. Chem. 272, 15591-15594 (1997).
32. Lebowitz PF, Sakamuor D, Prendergast CG: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachement. Cancer Res. 57, 708-713 (1997).
33. Chen Z, Sun J, Pradines A et al.: Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275, 17974-17978 (2000).
34. Raponi M, Lowenberg B, Lancet JE et al.: Identification of molecular predictors of response to Zarnestra (tipifarnib, R115777) in relapsed and refractory acute myeloid leukemia. Blood 104, 246a (2004).
35. Ashar HR, James L, Gray K et al.: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. (2000) 275, 30451-30457 (2004).
36. Ashar HR, James L, Gray K et al.: The farnesyltransferase inhibitor SCH66336 induces a G2?M or G1 pause in sensitive human tumor cell lines. Exper. Cell Res. 262, 17-27 (2001).
37. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM: The farnesyltransferase inhibitor FTI-2153 blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation accumulation during mitosis of human lung cancer cells. J. Biol. Chem. 276, 16161-16167 (2001).
38. Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of antiproliferative, proapoptotic and anti-angiogenic effects. Oncogene 18, 7514-7526 (1999).
39. Gu WZ, Tahir SK, Wang YC et al.: Effect of novel CAAX peptidomimetic farnesyl transferase inhibitor on angiogenesis in vitro and in vivo. 35, 1394-1401 (1999).
40. Peters DG, Hoover RR, Gerlach MJ et al.: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABLinduced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97, 1404-1412 (2001).
41. Reichert A, Heisterkamp N, Daley GQ, Groffen J: Treatment of Bcr-ABl positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyltransferase inhibitor SCH66336. Blood 97, 1399-1403 (2001).
42. Lancet JE, Willman CL, Bennett JM: Acute myelogenous and aging: clinical interactions. Hematol. Oncol. North Am. 14, 251-267 (2000).
43. Stone RM, Berg DT, George SL et al.: Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98, 548-553 (2001).
44. Bolanos-Meade J, Guo C, Gojo I, Karp JE: A Phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over age 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leuk. Res. 28, 571-577 (2004).
45. Grimwade D, Walker H, Harrison G et al.: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 98, 1312-1320 (2001).
46. Leith CP, Kopecky KJ, Chen IM et al.: Frequency and clinical significance of the expression of the multi-drug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 94, 1086-1099 (1999).
47. Karp JE, Lancet JE, Kaufmann SH et al.: Clinical and biological activity in the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical-correlative trial. Blood 97, 3361-3369 (2001).
48. Lancet JE, Gotlib J, Gojo I et al.: Tipifarnib (ZARNESTRA) in previously untreated poor-risk AMl of the elderly: updated results of a multicenter Phase 2 trial. Blood 104, 249a (2004).
49. Harousseau JL, Reiffers J, Lowenberg B et al.: Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter Phase 2 study. Blood 102, 176a (2003).
50. Kurzrock R, Albitar M, Cortes JE et al.: Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22, 1287-1292 (2004).
51. Kurzrock R, Kantarjian HM, Cortes JE et al.: Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the Phase 1 setting. Blood 102, 4527-4534 (2003).
52. Kurzrock R, Fenaux P, Raza A et al.: Highrisk myelodysplastic syndrome (MDS): first results of international Phase 2 study with oral farnesyltransferase inhibitor R115777 (ZARNESTRA). Blood 104, 23a (2004).
53. Kurzrock R, Verstovsek S, Wright JJ et al.: Phase I study using alternate week administration of the farnesyl transferase inhibitor R115777 (Zarnestra) in patients with myelodysplastic syndrome. Blood 104, 402a (2004).
54. Cortes J, Albitar M, Thomas D et al.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101, 1692-1697 (2004).
55. Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH: In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 17, 849-855 (2003).
56. Mesa RA, Camoriano JK, Geyer SM et al.: A Phase 2 consortium (P2C) trial of R115777 (Tipifarnib) in myelofibrosis with myeloid metaplasia. Blood 104, 422a
57. Gotlib J, Loh M, Lancet JE et al.: Phase I/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): interim results. Blood 102, 3425a (2003).
58. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG: R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol. Cancer Ther. 3, 179-186 (2004).
59. Le Gouill S, Pellat-Deceunynck C, Harousseau JL et al.: Farnesyl transferase inhibitor R115777 induces apoptosis in human myeloma cells. Leukemia 16, 1664-1667 (2002).
60. Alsina M, Fonseca R, Wilson EF et al.: Farnesyltransferase inhibitor tipifarnib is well-tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103, 3271-3277 (2004).
61. Zhu K, Gerbino E, Beaupre DM et al.: Farnsyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105, 4759-4766 (2005).
62. Topaly J, Zeller WJ, Fruehauf S: Potentiation of imatinib activity in chronic myelogenous leukemia cells by farnesyltransferase inhibitors. Blood 100, 318a (2002).
63. Cortes J, Garcia-Manero G, OBrien S et al.: A Phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients with chronic myeloid leukemia in chronic phase (CP) who failed IM therapy. Blood 104, 289a (2004).
64. Buzzeo R, Enkemann S, Nimmanapalli R et al.: Characterization of a R115777 resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin. Cancer Res. 11 (2005) (In press).
65. Prendergast GC, Davide JP, Lebowitz PF et al.: Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyltransferase inhibitors. Cancer Res. 56, 2626-2632 (1996).
66. Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR: Establishment and characterization of acquired resistance to farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin. Cancer Res. 8, 2002-2009 (2002).
67. Del Villar K, Urano J, Guo L et al.: A mutant form of protein Farnesyltransferase exhibits increase resistance to farnesyltransferase inhibitors. J. Biol. Chem. 27010-27017 (1999).
68. Raz T, Mohammad A, Daley GQ: Resistance to the farnesyl transferase inhibitor SCH66336 (Lonafarnib) caused by mutations in the target protein farnesyl transferase-a. Blood 104, 133a (2004).
69. Toksoz D, Williams DA: Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction proteins. Oncogene 9, 621-628 (1994).
70. Zheng Y, Olson MF, Hall A, Cerione RA, Toksoz D: Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J. Biol. Chem. 270, 9031-9034 (1995).
71. Carr DW, Stofka-Hahn RE, Fraser ID et al.: Interaction of the regulatory subunit (RII) of c-AMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J. Biol. Chem. 266, 14188-14192 (1991).
72. Foisner R, Traub P, Wiche G: Protein kinase A- and protein kinase C-regulated interaction of plectin with lamin B and vimentin. Proc. Natl Acad. Sci. USA 88, 3812-3816 (1991).